Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Potthast

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
European Radiology|June 4, 2002
Ultrasound and magnetic resonance imaging in Crohn's disease: a comparisonS Potthast, A Rieber, C Von Tirpitz, et al.
International Journal of Colorectal Disease|August 23, 2000
Diagnostic imaging in Crohn's disease: comparison of magnetic resonance imaging and conventional imaging methodsA Rieber, D Wruk, S Potthast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trialV Hess, S Pratsch, S Potthast, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
European Radiology|June 4, 2002
Ultrasound and magnetic resonance imaging in Crohn's disease: a comparisonS Potthast, A Rieber, C Von Tirpitz, et al.
International Journal of Colorectal Disease|August 23, 2000
Diagnostic imaging in Crohn's disease: comparison of magnetic resonance imaging and conventional imaging methodsA Rieber, D Wruk, S Potthast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trialV Hess, S Pratsch, S Potthast, et al.
Pageof 2